Abstracts tagged "DMARDs"

Abstract Number: 988 • 2019 ACR/ARP Annual Meeting
Translational Imaging of Treatment Effects for a Novel Anti-TNF-Steroid Antibody Drug Conjugate in a Rat Model of Rheumatoid Arthritis
Bradley Hooker¹, Xiaomeng Zhang ², Todd Cole ², Ann Tovcimak ², Shaughn Bryant ³, Lucy Phillips ³, David Blanchard ², Dustin Wooten ², Qi Guo ², Melanie Ruzek ³, Adrian Hobson ³, Michael McPherson ³, Robert Stoffel ³, Wendy Waegell ³ and Yanping Luo ², ¹AbbVie, North Chicago, IL, ²AbbVie, North Chicago, ³AbbVie, Worcester
Background/Purpose: Rheumatoid arthritis (RA) is an inflammatory joint disease of autoimmune etiology. If insufficiently treated, RA leads to joint damage and irreversible disability. Although there…
Abstract Number: 2369 • 2019 ACR/ARP Annual Meeting
Treatment Patterns with Disease Modifying Anti-rheumatic Drugs in United States Veterans with Newly Diagnosed Rheumatoid Arthritis, Psoriatic Arthritis, or Ankylosing Spondylitis
Rebecca Overbury¹, Shaobo Pei ², Gopi Penmetsa ³, Brian Sauer ², Vikas Patil ², Jodi Walker ⁴, Jerry Clewell ⁴, Kevin Douglas ⁴, Daniel Clegg ⁵, Grant Cannon ⁶, Ahmad Halwani ⁷ and Jessica Walsh ⁸, ¹Assisstant Professor, University of Utah, Salt Lake City, UT, ²Division of Epidemiology, Department of Internal Medicine, Salt Lake City Veteran Affairs and University of Utah Medical Centers, Salt Lake City, UT, ³Gopi K. Penmetsa, MD, Division of Rheumatology, Department of Internal Medicine, Salt Lake City Veteran Affairs and University of Utah Medical Centers, Salt Lake City, UT, ⁴AbbVie Inc., Salt Lake City, UT, ⁵University of Utah, Salt Lake City, UT, ⁶Salt Lake City VA Medical Center and Univeristy of Utah, Salt Lake City, UT, ⁷Division of Hematology, Department of Internal Medicine, Salt Lake City Veteran Affairs and University of Utah Medical Centers, Salt Lake City, UT, ⁸Division of Rheumatology, University of Utah, Salt Lake City, UT
Background/Purpose: Delays in treatment for inflammatory arthritis (IA) are associated with unfavorable outcomes, including impaired quality of life, irreversible joint damage, and disability. Our objective…
Abstract Number: 1194 • 2019 ACR/ARP Annual Meeting
Can an MDHAQ (Multidimensional Health Assessment Questionnaire) 60-Symptom Checklist to Monitor Early Medication Outcomes (MDHAQ/MEMO60) Detect Adverse Events of High-Risk Medications?
Sarah Abu Mehsen ¹, Isabel Castrejon ¹ and Theodore Pincus², ¹Rush University Medical Center, Chicago, IL, ²Division of Rheumatology, Rush University Medical Center, Chicago, IL
Background/Purpose: Adverse events of medications have been reported to account for 5% of hospital admissions in the US, and as many as 10% in the…
Abstract Number: 2394 • 2019 ACR/ARP Annual Meeting
Use and Influence of Biologic/Janus Kinase Monotherapy Among Recently Switched Rheumatoid Arthritis Patients: Results from an Annual National Patient Chart Audit
Lynn Price¹, Phil Pouliot ¹ and Lauren Schmitt ¹, ¹Spherix Global Insights, Exton, PA
Background/Purpose: US rheumatologists have long agreed that methotrexate (MTX) is the backbone of rheumatoid arthritis (RA) treatment, and while comfort with biologic/JAK monotherapy is growing,…
Abstract Number: 1334 • 2019 ACR/ARP Annual Meeting
Patterns of Fatigue in Rheumatoid Arthritis Patients Who Received Biological and Targeted Synthetic Disease-Modifying Antirheumatic Drugs
Dalifer Freites Nuñez¹, Leticia León ², Marta Redondo ³, Cristina Vadillo Font ⁴, Pia Lois ⁵, Arkaitz Mucientes Ruiz ⁴, Luis Rodríguez-Rodríguez ⁶, Benjamín Fernández Gutiérrez ⁷, Juan Angel Jover Jover ⁴ and lydia Abasolo Alcazar ⁴, ¹Hospital Clínico San Carlos, MADRID, Spain, ²Fundación para la Investigación Biomedica, Madrid, Madrid, Spain, ³Universidad Camilo José Ceja, Madrid, Madrid, Spain, ⁴HOSPITAL CLINICO SAN CARLOS, MADRID, Spain, ⁵Hospital Clínico San Carlos, Madrid, Madrid, Spain, ⁶Fundación para la Investigación Biomedica, Madrid, Spain, ⁷Hospital Clínico San Carlos, Madrid
Background/Purpose: Fatigue is one of the most frequent symptoms in patients with rheumatoid arthritis (RA), affecting more than 80% of them. The experience of fatigue…
Abstract Number: 2404 • 2019 ACR/ARP Annual Meeting
Does Combined Therapy Affects Adherence in Rheumatoid Arthritis?
Iván de Jesús Hernández-Galarza ¹, Rita Pineda-Sic¹, Marielva Castro-Gonzalez ¹, Diana Elsa Flores-Alvarado ¹, Octavio Ilizaliturri-Guerra ¹, Rodolfo Uriarte-Botello ¹ and Dionicio Galarza-Delgado ¹, ¹Universidad Autonoma de Nuevo Leon, Hospital Universitario "Dr Jose Eleuterio Gonzalez", Monterrey, Nuevo Leon, Mexico
Background/Purpose: Treatment adherence in Rheumatoid Arthritis (RA) patients vary from 30 to 80%. It is important to identify the associated factors to a low adherence,…
Abstract Number: 1340 • 2019 ACR/ARP Annual Meeting
Patterns of Sustained Remission and Subsequent DMARD Tapering in Early Rheumatoid Arthritis: Data from the Canadian Early Arthritis Cohort
Maria Powell¹, Vivian Bykerk ², Orit Schieir ³, Marie-France Valois ⁴, Susan J. Bartlett ⁵, Louis Bessette ⁶, Gilles Boire ⁷, Carol Hitchon ⁸, Edward Keystone ⁹, Janet Pope ¹⁰, Carter Thorne ¹¹, Diane Tin ¹² and Glen Hazlewood ¹, ¹University of Calgary, Calgary, AB, Canada, ²Hospital for Special Surgery, New York City, NY, ³University of Toronto Dalla Lana School of Public Health, Toronto, ON, Canada, ⁴McGill University, Montreal, Canada, ⁵McGill University, Montreal, QC, Canada, ⁶Laval University, Quebec City, QC, Canada, ⁷Sherbrooke University, Sherbrooke, QC, Canada, ⁸University of Manitoba, Winnipeg, Canada, ⁹Mount Sinai Hospital and University of Toronto, Toronto, ON, Canada, ¹⁰Western University, London, ON, Canada, ¹¹Southlake Regional Health Centre, Newmarket, ON, Canada, ¹²Southlake Regional Health Centre, Newmarket, Canada
Background/Purpose: Rheumatoid arthritis (RA) treatment emphasizes aggressive titration of disease-modifying antirheumatic drugs (DMARDs) with the goal of achieving disease remission. This often includes the use…
Abstract Number: 2479 • 2019 ACR/ARP Annual Meeting
Unmet Treatment Needs in Patients with Psoriatic Arthritis
Daniel Aletaha¹, Mihalina Georgallis ², Matthew Wallace ², Patrick Zueger ³ and Ruth Zeidman ², ¹Medical University of Vienna, Vienna, Austria, ²Covance Market Access & Phase IV Solutions, London, United Kingdom, ³AbbVie Inc., North Chicago
Background/Purpose: Despite significant advances in the treatment of psoriatic arthritis (PsA), disease control and remission remain a challenge. Research characterizing residual disease burden with current…
Abstract Number: 1380 • 2019 ACR/ARP Annual Meeting
Patient Characteristics, Treatment Patterns, and Treatment Persistency in Biologic DMARD-Experienced Rheumatoid Arthritis Patients in a US RA Registry
Robin Dore¹, Jenya Antonova ², Leslie Harrold ³, Lawrence Chang ², Emily Scherer ⁴, Angel Cronin ⁵, Kelechi Emeanuru ⁵ and Joel Kremer ⁶, ¹Private practice, Tustin, CA, ²Gilead Sciences, Foster City, CA, ³Corrona, LLC and University of Massachusetts Medical School, Worcester, MA, ⁴Corrona, LLC, Cambridge, MA, ⁵Corrona, LLC, Waltham, MA, ⁶Albany Medical College and The Center for Rheumatology; Corrona, LLC, Albany, NY
Background/Purpose: Multiple treatment options are available for patients with RA. ACR guidelines recommend initiating treatment with a conventional synthetic DMARD (csDMARD). If a patient fails…
Abstract Number: 2708 • 2019 ACR/ARP Annual Meeting
Effect of Immunogenicity on Efficacy and Safety of Subcutaneous or Intravenous Abatacept in Pediatric Patients with Polyarticular-Course JIA: Findings from Two Phase III Trials
Hermine Brunner¹, Nikolay Tzaribachev ², Ingrid Louw ³, Alberto Berman ⁴, Inmaculada Calvo Penadés ⁵, Jordi Antón ⁶, Francisco Ávila-Zapata ⁷, Rubèn J Cuttica ⁸, Gerd Horneff ⁹, Robert Wong ¹⁰, Mehmooda Shaikh ¹¹, Johanna Mora ¹¹, Marleen Nys ¹², Daniel J. Lovell ¹³, Alberto Martini ¹⁴ and Nicolino Ruperto ¹⁵, ¹Pediatric Rheumatology Collaborative Study Group (PRCSG), Cincinnati Children’s Hospital Medical Center, Cincinnati, OH, ²Pediatric Rheumatology Research Institute, Bad Bramstedt, Germany, ³Panorama Medical Centre, Parow, South Africa, ⁴Universidad Nacional de Tucuman and Centro Médico Privado de Reumatología, Tucuman, Argentina, ⁵Hospital Univ. La Fe, Valencia, Spain, ⁶Hospital Sant Joan de Déu, Barcelona, Spain, ⁷Star Medica Hospital, Merida, Yucatán, Mexico, ⁸Hospital General de Niños Pedro de Elizalde, Buenos Aires, Argentina, ⁹Asklepios Clinic Sankt Augustin, Sankt Augustin, Germany, ¹⁰Bristol-Myers Squibb, Princeton, ¹¹Bristol-Myers Squibb, Princeton, NJ, ¹²Bristol-Myers Squibb, Braine L’Alleud, Belgium, ¹³Pediatric Rheumatology Collaborative Study Group (PRCSG), Cincinnati Children’s Hospital Medical Center, Cincinnati, ¹⁴IRCCS Istituto Giannina Gaslini, Università degli Studi di Genova, Genova, Italy, ¹⁵Paediatric Rheumatology International Trials Organisation (PRINTO), Genoa, Italy
Background/Purpose: Patients (pts) with polyarticular-course JIA (pJIA) may develop anti-drug antibodies (ADAs) in response to biologics.1 Presence of ADAs has been associated with treatment (tmt)…
Abstract Number: 1389 • 2019 ACR/ARP Annual Meeting
Treatment Response to Biologic DMARDs in Patients with RA: A Retrospective Analysis of the RISE Registry
Xue Han¹, Joshua Bryson ¹, David C Crosby ¹, Michael Evans ² and Gabriela Schmajuk ³, ¹Bristol-Myers Squibb, Princeton, ²University of California San Francisco, San Francisco, ³UCSF, SFVAMC Division of Rheumatology, San Francisco, CA
Background/Purpose: ACR guidelines recommend treatment for patients with RA based on baseline (BL) disease activity. In patients with an inadequate response to conventional synthetic DMARDs,…
Abstract Number: 2846 • 2019 ACR/ARP Annual Meeting
Outcomes over the First 5 Years of Follow up in a Very Early Rheumatoid Arthritis (RA) Cohort Recruited over 20 Years: Most of the Improvement Occurred Before the 2011 Implementation of Treat-to-Target (T2T)
Nathalie Carrier ¹, Sophie Roux ², Ariel Masetto ², Artur deBrum Fernandes ², Patrick Liang ², Meryem Maoui ³ and Gilles Boire², ¹CIUSSS de l'Estrie-CHUS, Sherbrooke, QC, Canada, ²Université de Sherbrooke, Sherbrooke, QC, Canada, ³Bristol-Myers Squibb Canada, St-Laurent, QC, Canada
Background/Purpose: To analyze the evolution over 20 years of disease activity, treatments and radiographic progression over the first 5 years of follow up of patients…
Abstract Number: 1404 • 2019 ACR/ARP Annual Meeting
Treatments Patterns Among Patients with Rheumatoid Arthritis Treated with a Biologic Disease-modifying Anti-rheumatic Drug: A Nation-wide Study in Korea
Min Jung Kim¹, Anna Shin ², Seonghwan Shin ², You-Jung Ha ³, Yun Jong Lee ⁴, Eun Bong Lee ⁵, Yeong-Wook Song ¹ and Eun Ha Kang ³, ¹Seoul National University Hospital, Seoul, Republic of Korea, ²Seoul National University Bundang Hospital, Seongnam, Republic of Korea, ³Division of Rheumatology, Department of Internal Medicine, Seoul National University Bundang Hospital, Seongnam, Republic of Korea, Seongnam, Republic of Korea, ⁴Division of Rheumatology, Department of Internal Medicine, Seoul National University Bundang Hospital, Seongnam, Republic of Korea, ⁵Division of Rheumatology, Department of Internal Medicine, Seoul National University College of Medicine, Seoul, Korea, seoul
Background/Purpose: Limited data are available on whether patients with rheumatoid arthritis (RA) are treated with conventional disease-modifying anti-rheumatic drugs (cDMARDs) according to the current recommendations…
Abstract Number: 2906 • 2019 ACR/ARP Annual Meeting
DMARD-free Remission in Established Rheumatoid Arthritis: 2 Year Results of the TARA Trial
Elise van Mulligen¹, Angelique Weel ², Martijn Kuijper ², Mieke Hazes ¹, Annette van der Helm-van Mil ³ and Pascal de Jong ¹, ¹Erasmus MC, Rotterdam, Netherlands, ²Maasstad Hospital, Rotterdam, Netherlands, ³LUMC, Leiden, Zuid-Holland, Netherlands
Background/Purpose: In rheumatoid arthritis (RA) disease outcomes have improved enormously in the last decades. Due to early initiation of therapy, a treat-to-target approach and a…
Abstract Number: 1409 • 2019 ACR/ARP Annual Meeting
Comparison of Healthcare Resource Utilization and Costs of Type 2 Diabetes Mellitus (T2DM)-Related Complications in Medicare Beneficiaries with Rheumatoid Arthritis (RA) and T2DM Who Initiated Treatment with Abatacept versus Other Targeted Disease-Modifying Anti-Rheumatic Drugs
Vardhaman Patel¹, Zulkarnain Pulungan ², Anne Shah ², Barton Jones ², Allison Petrilla ², Leticia Ferri ³, Xue Han ³ and Kaleb Michaud ⁴, ¹Bristol-Myers Squibb, New York City, NY, ²Avalere, washington, DC, ³Bristol-Myers Squibb Company, Princeton, NJ, ⁴University of Nebraska Medical Center, Omaha, NE
Background/Purpose: Use of abatacept, a targeted DMARD (tDMARD), in patients with RA has shown to improve whole-body insulin sensitivity and reduce HbA1c levels.1 Comparative evidence…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].